Xiaoling Tong

5PUBLICATIONS
18CO-AUTHORS
Predictive and prognostic markersCancer geneticsMolecular targetsTime-series analysisCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Nov 09, 2021
Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes.

Si-Yang Liu, Hua Bao, Qun Wang

|Apr 03, 2021
The genomic landscape of young and old lung cancer patients highlights age-dependent mutation frequencies and clinical actionability in young patients.

Lei Cai, Yong Chen, Xiaoling Tong

|Sep 02, 2020
Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.

Meiying Cui, Yuchen Han, Pan Li

|May 16, 2020
Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors.

YanRu Qin, Hong Jian, Xiaoling Tong

|Dec 19, 2019
YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.

Honghai Dai, Yang W Shao, Xiaoling Tong

Pageof 1

Frequent Collaborators

2 joint publications

Hua Bao

1 joint publications

Zhe Yang

1 joint publications

Qiuxiang Ou

1 joint publications

Guozhong Jiang